Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?

Francesco Bellanti, Bertil Kågedal, Oscar Della Pasqua

Open source

DOI
10.1007/s00228-010-0966-3
Published
2011-02-02
Container
European Journal of Clinical Pharmacology
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s00228-010-0966-3,
  title = {Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?},
  author = {Francesco Bellanti and Bertil Kågedal and Oscar Della Pasqua},
  year = {2011},
  journal = {European Journal of Clinical Pharmacology},
  doi = {10.1007/s00228-010-0966-3},
  url = {https://doi.org/10.1007/s00228-010-0966-3}
}

RIS

TY  - JOUR
TI  - Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?
AU  - Francesco Bellanti
AU  - Bertil Kågedal
AU  - Oscar Della Pasqua
PY  - 2011
JO  - European Journal of Clinical Pharmacology
DO  - 10.1007/s00228-010-0966-3
UR  - https://doi.org/10.1007/s00228-010-0966-3
ER  - 

APA

Bellanti, F., Kågedal, B., & Pasqua, O. D. (2011). Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-010-0966-3

Source records